By Topic
Is Paradigm Biopharmaceuticals (ASX: PAR) Bottoming Out After Its Prolonged Downtrend?
Paradigm Biopharmaceuticals (ASX: PAR) is an Australian late-stage biotech developing injectable PPS, mainly for osteoarthritis. Its shares have fallen more than 95% since 2020 amid trial delays, dilution and losses, with August 2026 Phase 3 interim data now the key catalyst.
BPH Energy (ASX: BPH) Jumps 12.5% as Buyers Return to the Micro-Cap Explorer
BPH Energy shares surged 12.5% as investors focused on the upcoming PEP-11 court decision. The diversified micro-cap has exposure to gas exploration, hydrogen technology, and medical devices, with recent funding and project progress supporting renewed market interest.
Has Metallium (ASX: MTM) Found a Critical Demand Zone After Its Extended Downtrend?
Metallium (ASX: MTM), a pre-revenue metal recovery and exploration company, has lost momentum as commercialisation delays and cash-runway concerns replaced hype. Technically, MTM is testing major support near 0.475, but a confirmed reversal has not yet appeared.
Cyprium Metals (ASX: CYM): Re‑Emerging as Australia’s Next Copper Producer
Cyprium Metals (ASX: CYM) advances toward first copper cathode production at Nifty, backed by strong funding, disciplined execution, and a clear growth pipeline across Western Australia.
Core Lithium (ASX: CXO): Finniss Restart and Tactical Re‑rating
Core Lithium (ASX: CXO) advances its Finniss restart with full funding, disciplined execution, and improving lithium sentiment, positioning for a tactical rebound as operations resume and technical momentum builds.
.webp&w=828&q=75)
Northern Minerals (ASX: NTU): Rare-Earth Momentum Builds as NTU Tests a Make-or-Break Support Zone
Northern Minerals remains focused on advancing its Browns Range rare earths project while progressing FEED work and expanding resources at Dazzler. The stock is consolidating near key support as investors monitor funding, governance changes, and project milestones
...